This clinical trial is focused on studying a condition known as septic shock, which is a severe infection that causes dangerously low blood pressure and can lead to organ failure. The study is investigating the use of a medication called landiolol hydrochloride, which is administered as a solution through an intravenous infusion. The purpose of the study is to see if reducing the heart rate with landiolol can improve survival rates in patients experiencing septic shock with a fast heart rate and strong heart contractions.
Participants in the study will receive either the landiolol treatment or the standard care, which may include a placebo. The study will monitor patients over a period of 28 days to assess the impact of the treatment on their survival. During this time, researchers will also observe other factors such as the number of days patients need medications to support their heart, the length of time they require mechanical breathing support, and their overall stay in the hospital.
The study aims to provide valuable insights into whether landiolol can be an effective treatment option for patients with septic shock. By comparing the outcomes of those receiving landiolol with those receiving standard care, the study hopes to determine if this medication can help reduce the risk of death in these critically ill patients.
France 